Back to Search

PHILIP KANTOFF, MD

MD

Medical Oncology Physician

NPI: 1235107871Individual

Specialties, Licenses & Credentials

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

147233-1(NY)

Research & Publications (20)

Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.
PMID 19395186·Int J Radiat Oncol Biol Phys·2010
4-observational
Functional enhancers at the gene-poor 8q24 cancer-linked locus.
PMID 19680443·PLoS Genet·2009
8-other
Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
PMID 19549893·Cancer Res·2009
8-other
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.
PMID 19366828·Clin Cancer Res·2009
4-observational
Role of microRNA-221/-222 in cancer development and progression.
PMID 19625765·Cell Cycle·2009
8-other
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
PMID 19632176·Cell·2009
8-other
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
PMID 19528373·J Clin Oncol·2009
4-observational
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.
PMID 19351832·Cancer Res·2009
8-other
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
PMID 19431146·Int J Cancer·2009
8-other
Screening for prostate cancer.
PMID 19297563·N Engl J Med·2009
8-other
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
PMID 19213669·Clin Genitourin Cancer·2009
8-other
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
PMID 19152438·Cancer·2009
8-other
Phase II study of sunitinib in men with advanced prostate cancer.
PMID 19403935·Ann Oncol·2009
3-trial
Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.
PMID 19395184·Int J Radiat Oncol Biol Phys·2009
4-observational
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.
PMID 18980297·Cancer·2008
8-other
Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels.
PMID 18827812·Br J Cancer·2008
1-meta
No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.
PMID 18615538·Prostate·2008
8-other
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.
PMID 18613203·ChemMedChem·2008
8-other
Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort.
PMID 18583469·Cancer Epidemiol Biomarkers Prev·2008
4-observational
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
PMID 18565884·J Clin Oncol·2008
2-rct

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
1275 YORK AVE, SUITE C-1289
NEW YORK, NY 10065

Location

Practice Location

1275 YORK AVE, NEW YORK, NY
(212) 639-5393

Quick Facts

NPI
1235107871
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile